Industrial electronics giant AMETEK (NYSE:AME) delivered a strong top-line performance for the fourth quarter of 2025, surpassing revenue expectations with 13.4% year-over-year growth. However, a closer look reveals pressure on operating margins, painting a nuanced picture for the diversified manufacturer.
A decades-old estate plan unravels as one sibling uncovers evidence suggesting a brother secretly obtained half a million dollars meant for future generations, raising questions of elder financial abuse and legal recourse.
Merck & Co. reported solid fourth-quarter revenue growth driven by its blockbuster cancer drug Keytruda, but the pharmaceutical giant forecasts a slowdown in earnings growth as it absorbs billions in costs from recent acquisitions aimed at diversifying its pipeline ahead of Keytruda's patent expiration.
While the S&P 500 has surged, Berkshire Hathaway shares have treaded water, prompting a nuanced debate among analysts about the conglomerate's future in a tech-driven market.
In a candid television appearance, legendary Democratic strategist James Carville dismissed several high-profile names before identifying Illinois Governor J.B. Pritzker as a potential powerhouse for the party's 2028 presidential nomination, citing his fundraising prowess and an unconventional appeal to key voter blocs.
A growing number of incidents where hotels and gas stations refuse service to federal immigration officers has ignited a fierce national debate, pitting private business rights against accusations of discrimination and raising complex legal questions.
U.S. Attorney for D.C. Jeanine Pirro faces backlash after stating she would jail anyone bringing a firearm into the District, regardless of permits from other jurisdictions, igniting a debate over gun rights and federal enforcement.
India's Supreme Court has issued a stern warning to Meta's WhatsApp, questioning its data monetization and user consent model in a market where the app holds a dominant position. The court has temporarily barred data sharing pending a detailed examination.
Despite a double-digit decline in 2026, SoFi Technologies continues to post explosive growth. We examine whether the current dip below $25 presents a strategic entry point or a warning sign for investors.
Pfizer reported fourth-quarter revenue and profit that topped Wall Street forecasts, yet year-over-year sales dipped slightly. The pharmaceutical giant's results highlight the ongoing challenge of moving beyond its COVID-19 windfall.
Pharmaceutical giant Merck & Co. reported fourth-quarter revenue that surpassed Wall Street forecasts, driven by robust demand for its key products. However, a more conservative full-year sales projection and a sharp expected decline in earnings for the coming year tempered the positive results, sending shares lower in after-hours trading.
Packaging giant Ball Corporation (NYSE: BALL) delivered a robust fourth-quarter performance for 2025, surpassing revenue and profit expectations. The company's focus on operational discipline and shareholder returns, including $1.54 billion in buybacks and dividends, capped a record year.
Despite a robust 45% surge in earnings per share, Lonza Group AG (VTX:LONN) shareholders have seen their investment decline by 11% over the past year, starkly underperforming the broader Swiss market. This divergence underscores how investor sentiment and future expectations can overshadow even solid current financial performance.
As freezing temperatures grip the nation, federal regulators and consumer advocates are sounding the alarm on a predictable wave of scams. Fraudsters are exploiting the weather, posing as utility companies to pressure victims into immediate payments.
CNBC's Jim Cramer suggests that upcoming clinical trial updates for Eli Lilly's GLP-1 drugs, rather than quarterly earnings, are the primary catalyst investors should watch for potential stock movement.
CNBC's Jim Cramer includes Pfizer in his weekly game plan but voices unease over the pharmaceutical giant's pipeline, questioning where its next blockbuster drug will come from despite an attractive dividend yield.
CNBC's Jim Cramer has spotlighted Merck & Co. as a strategic holding, praising the pharmaceutical giant's acquisition-driven strategy to build a more balanced portfolio ahead of its blockbuster drug's patent cliff.
CNBC's Jim Cramer has placed Palantir Technologies on his radar ahead of its quarterly report, expressing confidence in the data analytics firm's performance and highlighting the combative leadership style of CEO Alex Karp.
President Trump's nomination of Kevin Warsh for Federal Reserve Chair places the former governor in a precarious position, tasked with navigating the President's demands for lower rates while maintaining the central bank's credibility.
HP Inc. announced an immediate leadership transition on Tuesday, appointing board member Bruce Broussard as interim CEO after Enrique Lores stepped down to pursue a new opportunity.
